Developments in molecular neuropathology have led to protein-based classification systems for neurodegenerative disorders. Key proteins include α-synuclein, amyloid and tau. Alternative mRNA splicing and post-translational change, induced by a bewildering variety of protein modifying processes such as phosphorylation and ubiquitination, have generated insights into new mechanisms of selective neuronal degeneration. The task now is to bring these developments in protein chemistry to the clinic, to try to determine whether this biochemical diversity can help in explaining the phenotypic variability that is so typical of neurodegeneration in general. In this review, we will explore the clinicopathological diversity of the tau-related disorders with specific reference to three of the most common tauopathies, frontotemporal dementia (familial and sporadic), progressive supranuclear palsy and corticobasal degeneration.
The clinical picture of FTD (frontotemporal dementia), CBD (corticobasal degeneration) and PSP (progressive supranuclear palsy) FTD FTD, a heterogeneous group of related conditions with variations in presentation, pathology and molecular pathogenesis is the second most prevalent form of neurodegenerative dementia in people of age less than 65 years with an estimated prevalence of 15 in 10 000 [1] . Between one-third and one-half of all cases are inherited (usually in an autosomal dominant pattern) and thus far 34 FTD-associated mutations have been identified in the tau gene on chromosome 17 (Table 1) . Almost all of these inherited disorders are characterized pathologically by the presence of tau-positive lesions in neurons and/or glial cells. However, it has been estimated that a majority of clinical FTD cases lack immunohistochemical evidence of tau pathology; this group includes DLDH (dementia lacking distinctive histopathology), FTD/MND (motor neuron disease) inclusion body disease and FTD with ubiquitin-positive, tau-negative inclusions. The relationship between tau-related FTD and these clinically identical disorders, some of which are also inherited, remains to be resolved. Clinically speaking, FTD can be broadly classified into behavioural and aphasic variants and each can be further subdivided into frontal and temporal types [2] . The behavioural frontal variant may present with orbitofrontal lobe dysfunction, such as early personality change and disinhibition or with a medial frontal (anterior cingulate)-type presentation with apathy, abulia, mutism, apraxia, perseveration, stereotyped movements/behaviours and hyperorality. A dorsolateral frontal lobe presentation will usually include disorganization and an inability to plan ahead or to carry out tasks that require sequential organization. In the behavioural temporal variant, where there is a degeneration of the nondominant anterior temporal lobe, patients display selfishness/ callousness, antisocial traits, a lack of empathy and often the emergence of new artistic or musical talents/tastes.
The language or aphasic variants of FTD reflect degeneration of the dominant posterior temporal or inferior frontal lobes: the frontal aphasic variant, also known as primary progressive aphasia, is characterized by halting, agrammatic speech with frequent paraphasic errors but relatively preserved comprehension. The temporal aphasic variant, sometimes also called SD (semantic dementia), features impaired comprehension and word-finding deficits (especially for naming of nouns and written words).
As FTD progresses, the various subtypes merge so that patients develop combinations of clinical syndromes and eventually progress to a global dementia. FTDP (FTD with Parkinsonism) patients may present with early Parkinsonian features, only to develop later the behavioural aspects of the disease. In general, patients with mutations in exon 10 and the splice site upstream of exon 10 present with FTD and Parkinsonism, whereas mutations in other exons may present with the clinical features of classic Pick's disease or even with CBD or PSP-like features (Table 1) . Patients with either sporadic or inherited FTD may also either present with or later develop overt clinical features of MND (typically bulbar dysfunction), and up to half of all MND cases have neuropsychological evidence of frontal executive dysfunction [3] . Furthermore, 'defining clinical features' of CBD or PSP such as apraxia and supranuclear gaze deficits may develop during the course of FTD. Mean duration of FTD depends on the clinical presentation: in one series, the mean duration for frontal variant FTD was 6 ± 1.1 years and for MND/FTD, it was 3 ± 0.4 years; disease duration was longer in those with tau-positive disease [4] . The familial forms of FTD display variations in clinical phenotype and in rates of disease progression, but apart from positive family histories they are not actually distinguishable from the sporadic disease [5] .
PSP (Steele-Richardson-Olszewski disease)
PSP has an estimated incidence and prevalence similar to that of MND (1-2 and 5-6 in 100 000 respectively) with mean disease duration of approx. 8 years. The clinical picture is one of insidious onset with slowly progressive gait instability, a tendency to fall backwards (retropulsions), early freezing and frequent falls. However, the typical idiopathic PD (Parkinson's disease) tremor is usually absent: in its place is a marked non-levodopa responsive axial rigidity. The pathognomonic supranuclear gaze palsy is not a common early feature but is usually preceded by square wave jerks and slow vertical saccades, which, when fully developed, are particularly prominent on attempted downgaze [6] . Patients may also develop prominent pseudobulbar palsy and slowness in cognitive processing (bradyphrenia). Further studies on cognition in PSP have identified frontal-type executive dysfunctions that correlate with the gradual atrophy of the frontal lobe as detected on serial cerebral imaging [7] .
Corticobasal ganglionic degeneration
Of the three tau-related disorders, CBD is the least common. Characterized by limb apraxia (inability to perform a previously learned task in the presence of normal motor and sensory function), dystonia, cortical sensory loss, tremor, levodopa unresponsiveness and, occasionally, the alien limb phenomenon, there is prominent asymmetric atrophy of the contralateral frontoparietal lobes. However, some patients exhibit a prominent frontotemporal pattern of cognitive deficits (especially a progressive non-fluent aphasia, impaired awareness of deficit and personality change) and even supranuclear gaze palsy [8, 9] . CBD is insidious in onset and progresses to involve both hemispheres until an end-stage dementia develops. Mean disease duration is approx. 8 years [10] . Although true familial instances of PSP and CBD are exceptional, both share a common tau haplotype (the H1 haplotype) in the region of the tau gene [11] [12] [13] [14] . The fact that there is often a positive family history of other neurological features such as tremor, Parkinsonism or presumed 'stroke' in patients with PSP/CBD lends weight to the possibility of an as yet unidentified genetic susceptibility factor in the neighbourhood of the tau haplotype. It is noticeable that several of the familial forms of FTDP-17 overlap at both clinical and pathological levels with PSP and CBD; just as many cases of FTD (sporadic or familial) develop signs of MND at either the clinical and/or pathological level (Table 1 ) [15] [16] [17] [18] . As such, it can be difficult to make an early or accurate diagnosis and it is thus all too common that the diagnosis is made quite late or is not made at all.
Neuropathology
Despite the publication of consensus criteria for the pathological diagnosis of FTD, PSP and CBD, the modern literature abounds with distinct clinical examples where neuropathologic features, common to each of the three disorders, co-exist. Early FTD is characterized by linear superficial spongiosis of laminae 2 and 3 of the cerebral cortex with prominent neuronal loss and gliosis. With disease progression comes more extensive and widespread cellular loss with taupositive intraneuronal and glial cell inclusion bodies and tau-positive neuritic processes: the underlying tau biochemistry often deviates from the normal 1:1 ratio of 4R (4 repeat) to 3R tau (Table 1) [2, [19] [20] [21] . One of the most common FTD disorders, Pick's disease, is associated with asymmetrical frontotemporal lobar atrophy with tau-positive argentophilic intraneuronal inclusion bodies (Pick bodies) and ballooned neurons called Pick cells. The neuronal tau inclusions are usually of the 3R isoform, but, in some instances, neighbouring glial cells actually contain 4R tau inclusion bodies.
The absence of tau immunopositivity in some patients with FTD has led to the term DLDH, but because this group has reduced soluble tau levels without the accumulation of insoluble tau, it has been proposed (although not universally accepted) that this also constitutes a legitimate tauopathy subgroup [20, 21] . The motor neuron inclusion body disease, characterized by ubiquitin-positive but tau-negative intraneuronal inclusions, in an MND-type distribution may be seen in those with FTD phenotypes with or without clinical features of MND (Figure 1) .
The pathological criteria for CBD are asymmetrical frontoparietal cortical atrophy with achromatic ballooned neurons, degeneration of the substantia nigra and tau-positive neuronal and glial inclusions (especially astrocytic pla- Figure 1 Proposed mechanisms of tau-related neurodegeneration [38] Normal human adult tau protein is an oligomer of 3R and 4R tau proteins in the ratio 1:1 (top). Tau binds to microtubules where it is important in their assembly and stabilization. Low levels of tau mRNA have been identified in DLDH and HDDD2 (hereditary dysphasic disinhibition dementia 2) cerebral tissue, suggesting that low levels of soluble tau may be pathogenic but it has also been argued that these low levels simply reflect the degree of overall neuronal loss (far left). Mutations in the splice site adjacent to exon 10 lead to abnormal ratios of 3R to 4R tau, thus disrupting the binding affinity of the tau oligomers for the microtubule whilst also leading to accumulation of unbound tau into potentially toxic intracellular protein aggregates (or toxic intermediates) (centre left). Other mutations may also disrupt the binding site of tau and lead to aggregation of unbound mutant tau (centre right). Rare mutations at the splice site (+19, +29) may lead to increased soluble 3R tau levels that in turn appear to be rapidly acted upon by proteolytic enzymes (far right). The interaction of mutant or wild-type tau with other intracellular proteins and kinases may also contribute to the tauopathy phenotype.
ques and widespread white matter-predominant thread-like inclusions [22] ).
For PSP, the diagnostic criteria include subcortical neuronal and glial loss with tau-positive globose neurofibrillary tangles, astrocytic tufts and grumose degeneration of the cerebellar dentate nucleus [23] . PSP may be distinguished from CBD using immunoblotting of sarkosyl insoluble extracts of brain, which consistently yield a 33 kDa cleavage product in PSP and a 37 kDa cleavage product in CBD [24] .
There is a considerable overlap in the pathological features of CBD and PSP [25] and also between CBD, PSP and several forms of FTDP-17 ( Figure 2 ). In patients with behavioural FTD or SD, it is difficult to predict the underlying pathology. But in patients presenting with progressive nonfluent aphasia, asymmetrical apraxia or clinical features of MND, respective pathologies of Pick's disease, CBD and MND-pattern ubiquitinated inclusions are consistently present [26] . Another difficulty is the presence of inter-and intra-familial phenotypic variations in the presence of the same tau mutation. Most patients with the P301L (Pro 301 → Leu) tau mutation, for example, have atrophy of the frontal and temporal cortices with widespread tau-positive neurons and glial cells. However, ballooned neurons and a distribution of tangles similar to that seen in PSP are only present in some family members. Small argyrophilic ubiquitin-negative tau-positive cytoplasmic aggregates called mini-Pick bodies have been described in the dentate gyrus granule cells in just some P301L families [27] . As mentioned previously, true Pick bodies are replete with 3R tau protein, whereas these miniPick-like bodies are 4R tau in type.
Tauopathy phenocopies are common and one must be rigorous in the exclusion of any alternative cause for these clinical conditions. PSP, CBD and FTD phenotypes have been described in Creutzfeldt-Jakob disease, antiphospholipid antibody syndrome, progressive multifocal leucoencephalopathy, vascular disease, neurosyphilis, C212Y-parkin mutation, presenilin-1 mutation, Alzheimer's disease and the recently characterized Neurofilament Inclusion Body Disease (FTD, CBD and MND in combination). Furthermore, it is now apparent that reduced penetrance may account for some apparently non-familial FTD patterns [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] .
Conclusions
In the absence of consistent and uniquely distinguishing clinical characteristics for the tauopathy disorders, it is likely that late and missed diagnoses will impact upon the potential benefits of any disease-specific therapeutic agents that may be developed in the future. Well-designed prospective natural history studies that rigorously follow the course of each of the clinical syndromes from clinical diagnosis to death are also required if one is to evaluate the effects of any such future treatment.
